0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters | Less Is More

Severity of Comorbidity and Non–Prostate Cancer Mortality in Men With Early-Stage Prostate Cancer FREE

Timothy Daskivich, MD; Natalia Sadetsky, MD, PhD; Sherrie H. Kaplan, PhD, MPH; Sheldon Greenfield, MD; Mark S. Litwin, MD, MPH
[+] Author Affiliations

Author Affiliations: Department of Urology, David Geffen School of Medicine (Dr Daskivich), and Department of Health Services, School of Public Health, and Jonsson Comprehensive Cancer Center (Dr Litwin), University of California, Los Angeles; Department of Urology, University of California, San Francisco (Dr Sadetsky); and Center for Health Policy Research and Department of Medicine, University of California, Irvine (Drs Kaplan and Greenfield).


Arch Intern Med. 2010;170(15):1396-1397. doi:10.1001/archinternmed.2010.251.
Text Size: A A A
Published online

Comorbidity is a key consideration in clinical decision making for prostate cancer. Early-stage prostate cancer often follows an indolent course, with the significant survival advantage of definitive local therapy developing at 8 years after treatment.1 Men with severe comorbidity may not live long enough to benefit from aggressive therapy and therefore may prefer to treat their disease conservatively. Unfortunately, the lack of a standardized and practical comorbidity assessment tool has limited the application of comorbidity to clinical decision making in this setting.

We have previously reported on the short-term prognostic utility of the Total Illness Burden Index for Prostate Cancer (TIBI-CaP), a patient-reported, questionnaire-based comorbidity assessment tool specifically designed for clinical use in prostate cancer.2,3 The TIBI-CaP is an 84-item questionnaire in 11 disease subdimensions that measures both presence and severity of comorbid illness and can be completed by a patient in 15 minutes. Men with the highest TIBI-CaP scores (≥12) were 13 times more likely to die of causes other than prostate cancer within 3.5 years of questionnaire administration, compared with men with the lowest scores.3 We recently followed this cohort for a median of 6.2 years after treatment to determine the utility of the TIBI-CaP in predicting long-term survival outcomes.

In 2002, the TIBI-CaP questionnaire was sent to 4635 active participants of the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national, observational prostate cancer registry.4 Of the 3389 men who returned the questionnaire, 2900 completed it and were included in the study. The mean time from treatment to TIBI-CaP questionnaire completion was 41.4 months. Our primary outcome was death from causes other than prostate cancer, measured from the time of treatment. We used multivariate Cox proportional hazards regression to assess the association of TIBI-CaP score and nonprostate cancer mortality, while controlling for clinical and demographic factors.

After a median follow-up of 6.2 years, overall mortality was 14.5% (420 men), while prostate cancer-specific mortality was only 3% (86 men). Nonprostate cancer-specific mortality was significantly different among comorbidity groups; 41% of patients with the highest TIBI-CaP scores (≥12) died of causes other than prostate cancer, compared with 6% of those with the lowest scores (0-2) (P < .001) (Table). In multivariate analysis, higher TIBI-CaP comorbidity scores were significantly associated with elevated risk of non–prostate cancer mortality. Men with the highest TIBI-CaP scores were 10 times more likely to die of causes other than prostate cancer, compared with men with the lowest scores (hazard ratio, 10.3; 95% confidence interval, 5.4-19.5) (Table).

Table Graphic Jump LocationTable. Survival Rates and Hazard Ratios for Death for Non–Prostate Cancer Mortality by Global TIBI-CaP Score

For men considering aggressive vs conservative treatment for clinically localized prostate cancer, comorbidity must be a primary consideration. Our data show that men with significant comorbidity (ie, TIBI-CaP ≥12) have a 41% risk of death from other causes 6 years after treatment, several years before significant survival benefits of aggressive local treatment can be realized.1 Because men with significant comorbidity have a high likelihood of short- to intermediate-term mortality, they may wish to strongly consider conservative over aggressive treatment for their clinically localized prostate cancer.

Although other comorbidity assessment tools such as the Index of Coexistent Disease, Charlson Comorbidity Index, and the Kaplan-Feinstein Index have been validated for use in prostate cancer,5 their clinical utility is limited by the infeasibility of thorough medical record review during an office visit. The TIBI-CaP, which can be completed by a patient in 15 minutes in the waiting room, offers a practical solution to this problem. Although formal comorbidity assessment may be unwarranted for men with minimal comorbidity, we believe that men with moderate or severe comorbidity ought to be offered this simple questionnaire to inform their decision making.

Correspondence: Dr Daskivich, Department of Urology, University of California, Los Angeles, PO Box 951738, Los Angeles, CA 90095-1738 (tdaskivich@mednet.ucla.edu).

Author Contributions:Study concept and design: Daskivich, Kaplan, Greenfield, and Litwin. Acquisition of data: Sadetsky. Analysis and interpretation of data: Daskivich, Sadetsky, Kaplan, Greenfield, and Litwin. Drafting of the manuscript: Daskivich. Critical revision of the manuscript for important intellectual content: Sadetsky, Kaplan, Greenfield, and Litwin. Statistical analysis: Daskivich and Sadetsky. Obtained funding: Litwin. Study supervision: Kaplan, Greenfield, and Litwin.

Financial Disclosure: None reported.

Bill-Axelson  AHLRuutu  MHäggman  M  et al. Scandinavian Prostate Cancer Group Study No. 4, Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352 (19) 1977- 1984
PubMed Link to Article
Stier  DMGreenfield  SLubeck  DP  et al.  Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology 1999;54 (3) 424- 429
PubMed Link to Article
Litwin  MSGreenfield  SElkin  EPLubeck  DPBroering  JMKaplan  SH Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer 2007;109 (9) 1777- 1783
PubMed Link to Article
Lubeck  DPLitwin  MSHenning  JM  et al. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor, The CaPSURE database: a methodology for clinical practice and research in prostate cancer. Urology 1996;48 (5) 773- 777
PubMed Link to Article
Albertsen  PCFryback  DGStorer  BEKolon  TFFine  J The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996;156 (1) 127- 132
PubMed Link to Article

Figures

Tables

Table Graphic Jump LocationTable. Survival Rates and Hazard Ratios for Death for Non–Prostate Cancer Mortality by Global TIBI-CaP Score

References

Bill-Axelson  AHLRuutu  MHäggman  M  et al. Scandinavian Prostate Cancer Group Study No. 4, Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352 (19) 1977- 1984
PubMed Link to Article
Stier  DMGreenfield  SLubeck  DP  et al.  Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology 1999;54 (3) 424- 429
PubMed Link to Article
Litwin  MSGreenfield  SElkin  EPLubeck  DPBroering  JMKaplan  SH Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer 2007;109 (9) 1777- 1783
PubMed Link to Article
Lubeck  DPLitwin  MSHenning  JM  et al. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor, The CaPSURE database: a methodology for clinical practice and research in prostate cancer. Urology 1996;48 (5) 773- 777
PubMed Link to Article
Albertsen  PCFryback  DGStorer  BEKolon  TFFine  J The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996;156 (1) 127- 132
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 6

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com

Users' Guides to the Medical Literature
Comorbidity


Comorbidity